![]() |
CC-90009
- 英文名称:CC-90009
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11005
- cas:1860875-51-9
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-05-23
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11005 |
用途 | 科研检测 |
英文名称 | CC-90009 |
包装规格 | 1MG |
CAS编号 | 1860875-51-9 |
别名 | CC-90009 |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:>98% by HPLC ,;NMR (Conforms)
分子式:C22H18ClF2N3O4
分子量:461.85
溶剂:DMSO (50 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):Cereblon modulator/Molecular glue
Function / Pharmacology:CC-90009 is a modulator of the cullin ring ligase 4-cereblon E3 ubiquitin ligase complex that specifically targets GSPT1 (G1 to S phase transition 1; EC50 = 9 nM; also known as eRF3a) instead of Ikaros (IKZF1) and Aiolos (IKZF3).1 It rapidly induced apoptosis and reduced leukemia engraftment and leukemia stem cells across a wide spectrum of acute myeloid leukemia xenograft patient samples including refractory/relapsed cases.2 The anti-AML activity of CC-90009 was shown to be regulated by multiple signaling pathways including the ILF/ILF3 complex, mTOR, and the integrated stress response. CC-90009 was able to potentiate premature termination codon (PTC; 11% of all genetic lesions in patients with inherited diseases contain this type of mutation) readthrough by aminoglycosides via degradation of eukaryotic release factors 1 (eRF1) and 3 (eRF3a/b) in various heritable disease models.3 It was also able to enhance aminoglycoside PTC readthrough of the mutated retinoblastoma (RB1) gene in MDA-MB-436 breast carcinoma cells and SW1783 astrocytoma cells.4
分子式:C22H18ClF2N3O4
分子量:461.85
溶剂:DMSO (50 mg/ml)
性状:White solid
存储:-20°C
Activity (short version):Cereblon modulator/Molecular glue
Function / Pharmacology:CC-90009 is a modulator of the cullin ring ligase 4-cereblon E3 ubiquitin ligase complex that specifically targets GSPT1 (G1 to S phase transition 1; EC50 = 9 nM; also known as eRF3a) instead of Ikaros (IKZF1) and Aiolos (IKZF3).1 It rapidly induced apoptosis and reduced leukemia engraftment and leukemia stem cells across a wide spectrum of acute myeloid leukemia xenograft patient samples including refractory/relapsed cases.2 The anti-AML activity of CC-90009 was shown to be regulated by multiple signaling pathways including the ILF/ILF3 complex, mTOR, and the integrated stress response. CC-90009 was able to potentiate premature termination codon (PTC; 11% of all genetic lesions in patients with inherited diseases contain this type of mutation) readthrough by aminoglycosides via degradation of eukaryotic release factors 1 (eRF1) and 3 (eRF3a/b) in various heritable disease models.3 It was also able to enhance aminoglycoside PTC readthrough of the mutated retinoblastoma (RB1) gene in MDA-MB-436 breast carcinoma cells and SW1783 astrocytoma cells.4